Eiger BioPharmaceuticals (STU:72C) Pretax Margin %: -448.97% (As of Dec. 2023)

What is Eiger BioPharmaceuticals Pretax Margin %?

Eiger BioPharmaceuticals STU:72C 10 Pretax Margin % is -448.97% as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Eiger BioPharmaceuticals's Pre-Tax Income for the six months ended in Dec. 2023 was €-28.87 Mil. Eiger BioPharmaceuticals's Revenue for the six months ended in Dec. 2023 was €6.43 Mil. Therefore, Eiger BioPharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was -448.97%.

The historical rank and industry rank for Eiger BioPharmaceuticals's Pretax Margin % or its related term are showing as below:

STU:72C's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -89.375
* Ranked among companies with meaningful Pretax Margin % only.

Eiger BioPharmaceuticals (STU:72C) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Eiger BioPharmaceuticals Pretax Margin % Related Terms

Eiger BioPharmaceuticals Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Pretax Margin % Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pretax Margin %

Get a 7-Day Free Trial

0.00

-278.80

-717.53

-475.22

Eiger BioPharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pretax Margin %	Get a 7-Day Free Trial															-657.88	-777.52	-496.25	-448.97	-2,339.51

STU:72C vs EDSA, SIGY, EVLO: Pretax Margin % Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Pretax Margin % falls into.

Save Embed

10GF Score

Eiger BioPharmaceuticals Inc STU:72C

Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Eiger BioPharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Eiger BioPharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-68.736	/	14.464
	=	-475.22 %

Eiger BioPharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-28.869	/	6.43
	=	-448.97 %

Frequently Asked Questions Learn more about Pretax Margin % →

What does a Pretax Margin % of -448.97% mean?

Eiger BioPharmaceuticals (STU:72C) has a Pretax Margin % of -448.97% as of Dec. 2023. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Eiger BioPharmaceuticals and its competitors.

Is Eiger BioPharmaceuticals' Pretax Margin % too high?

Eiger BioPharmaceuticals' current Pretax Margin % is -448.97%. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Eiger BioPharmaceuticals' Pretax Margin % compare to EDSA and SIGY?

Eiger BioPharmaceuticals' Pretax Margin % of -448.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Pretax Margin % for a Biotechnology company?

A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Pretax Margin % mean?

A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Pretax Margin % is -448.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Eiger BioPharmaceuticals stock overvalued right now?

Eiger BioPharmaceuticals (STU:72C) has a current Pretax Margin % of -448.97%. The current Pretax Margin % is -448.97%. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Pretax Margin % calculated?

Pretax Margin % is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Pretax Margin % is -448.97% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA SIGY EVLO GTBP IMNN NHWK TMBR GRTX CMRA ONVO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

10GF Score

Get the complete analysis for STU:72C

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18

Price

View STU:72C Analysis

See Pretax Margin % data for all stocks →